123dartist / shutterstock.com
Teva and South Korean biopharmaceutical company Celltrion have entered into an exclusive partnership to commercialise two of Celltrion’s biosimilars in the US and Canada.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Teva, Celltrion, biosimilar, EMA, partnership